EVOlve your treatment with extracellular vesicles derived from plants.
We use extracellular vesicles from plants and fruits to create new technology platforms for wound care therapy and drug delivery.
2i3T is the company for the management of the business incubator and for the technology transfer of the Turin’s University, that takes care of enhancing the results of academic research in an economic key, by promoting and supporting the creation of new companies with a high knowledge content.
2i3T it’s an hub were Innovative ideas, future entrepreneur, industry needs, investors and finance meet to boost new intensive knowledge startups.
Latest news
PUBLICATION
17th March 2023
Turin
EvoBiotech is proud to announce its latest publication on the use of extracellular vesicles derived from plants as a drug delivery system in the special issue “Advances of Membrane Vesicles in Drug Delivery Systems” of Pharmaceutics Journal. This work demonstrates the use of edible plant-derived extracellular vesicles to vehicle mRNA-based vaccines for SARS-CoV-2 using intramuscular, […]
PUBLICATION
27th January 2023
Turin
An Opinion paper entitled “Plant-Derived Extracellular Vesicles as a Platform for Drug Delivery” was just published in Innovations in Tissue Engineering & Regenerative Medicine. The publication describes the advantages of plant-derived extracellular vesicles as carriers and their relevance for the future of drug delivery. The complete article at the link: https://crimsonpublishers.com/iterm/pdf/ITERM.000523.pdf
GOALS
24th January 2023
Turin
Evobiotech received the recognition for the successful completion of the incubation program 2019-2022 of Incubatore d’Imprese 2i3T. Three years of growth and activities that brought the company to develop multiple therapeutic platforms using plant-derived extracellular vesicles.